Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Publication ,  Journal Article
Nussbaum, N; George, DJ; Abernethy, AP; Dolan, CM; Oestreicher, N; Flanders, S; Dorff, TB
Published in: Prostate Cancer Prostatic Dis
June 2016

BACKGROUND: Contemporary therapies for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements, which do not account for patient experience and health-related quality of life (HRQoL). METHODS: This literature review included a search of MEDLINE for randomized clinical trials enrolling ⩾50 patients with mCRPC and reporting on patient-reported outcomes (PROs) since 2010. RESULTS: Nineteen of 25 publications describing seven treatment regimens (10 clinical trials and nine associated secondary analyses) met the inclusion criteria and were critically appraised. The most commonly used measures were the Functional Assessment of Cancer Therapy-Prostate (n=5 trials) and Brief Pain Inventory Short Form (n=4 trials) questionnaires. The published data indicated that HRQoL and pain status augmented the clinical efficacy data by providing a better understanding of treatment impact in mCRPC. Abiraterone acetate and prednisone, enzalutamide, radium-223 dichloride and sipuleucel-T offered varying levels of HRQoL benefit and/or pain mitigation versus their respective comparators, whereas three treatments (mitoxantrone, estramustine phosphate and docetaxel, and cabazitaxel) had no meaningful impact on HRQoL or pain. The main limitation of the data were that the PROs utilized were not developed for use in mCRPC patients and hence may not have comprehensively captured symptoms important to this population. CONCLUSIONS: Recently published randomized clinical trials of new agents for mCRPC have captured elements of the patient experience while on treatment. Further research is required to standardize methods for measuring, quantifying and reporting on HRQoL and pain in patients with mCRPC in the clinical practice setting.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2016

Volume

19

Issue

2

Start / End Page

111 / 121

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Quality of Life
  • Prostatic Neoplasms, Castration-Resistant
  • Neoplasm Metastasis
  • Male
  • Immunotherapy
  • Humans
  • Combined Modality Therapy
  • Clinical Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nussbaum, N., George, D. J., Abernethy, A. P., Dolan, C. M., Oestreicher, N., Flanders, S., & Dorff, T. B. (2016). Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis, 19(2), 111–121. https://doi.org/10.1038/pcan.2015.42
Nussbaum, N., D. J. George, A. P. Abernethy, C. M. Dolan, N. Oestreicher, S. Flanders, and T. B. Dorff. “Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.Prostate Cancer Prostatic Dis 19, no. 2 (June 2016): 111–21. https://doi.org/10.1038/pcan.2015.42.
Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):111–21.
Nussbaum, N., et al. “Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.Prostate Cancer Prostatic Dis, vol. 19, no. 2, June 2016, pp. 111–21. Pubmed, doi:10.1038/pcan.2015.42.
Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):111–121.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2016

Volume

19

Issue

2

Start / End Page

111 / 121

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Quality of Life
  • Prostatic Neoplasms, Castration-Resistant
  • Neoplasm Metastasis
  • Male
  • Immunotherapy
  • Humans
  • Combined Modality Therapy
  • Clinical Trials as Topic